Impella as Bridge to Durable Left Ventricular Assist Device in Acute Myocardial Infarction Cardiogenic Shock Patients.
Journal
ASAIO journal (American Society for Artificial Internal Organs : 1992)
ISSN: 1538-943X
Titre abrégé: ASAIO J
Pays: United States
ID NLM: 9204109
Informations de publication
Date de publication:
28 Mar 2024
28 Mar 2024
Historique:
medline:
27
3
2024
pubmed:
27
3
2024
entrez:
27
3
2024
Statut:
aheadofprint
Résumé
Implantation of durable left ventricular assist device (LVAD) in cardiogenic shock (CS) patients after acute myocardial infarction (AMI) poses specific challenges (small left ventricular size, acute infarct area, need for antithrombotic therapy, status Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) 1 with impaired organ function and derangements in coagulation and inflammatory parameters) which may affect outcomes. We reviewed data of all AMI-CS patients who were implanted LVAD after Impella support at a referral center with the aim to analyze feasibility, timing, and outcomes of durable LVAD implantation after tMCS with Impella due to AMI-CS. Twenty-one patients were treated between 2013 and 2023: all were in Society for Cardiovascular Angiography & Interventions (SCAI) class D-E and INTERMACS 1-2 at presentation, median LV ejection fraction (EF) and LV end-diastolic diameter (EDD) were 15 (10-20)% and 57 (54-60) mm, respectively. Eleven patients (52%) were supported with Impella CP, seven with Impella 5.0 (33%), and three (14%) with Impella 2.5. Axillary cannulation was performed in nine patients (43%). Five patients (24%) had concomitant venoarterial extracorporeal membrane oxygenation (VA-ECMO) support. Median duration of Impella support was 12 (8-14) days. Overall, the use of Impella was characterized by low rate of complications and allowed successful bridge to durable LVAD in all patients, with 100% 30 day survival rate.
Identifiants
pubmed: 38537063
doi: 10.1097/MAT.0000000000002201
pii: 00002480-990000000-00452
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © ASAIO 2024.
Déclaration de conflit d'intérêts
Disclosure: M.P., S. Alticcio, P.N., A.O., and A.M.S. received speaker fee by Abiomed GmbH. M.P. received consultancy fee by Abiomed GmbH. The other authors have no conflicts of interest to report.
Références
Bernhardt AM, Potapov E, Vandenbriele C, Skurk C, Bertoldi LF, Pappalardo F: Differential utilization of Impella devices, extracorporeal membrane oxygenation, and combined therapies as escalation and de-escalation strategies. Eur Heart J Suppl 25: I32–I38, 2023.
Bertoldi LF, Pappalardo F, Lubos E, et al.: Bridging INTERMACS 1 patients from VA-ECMO to LVAD via Impella 5.0: De-escalate and ambulate. J Crit Care 57: 259–263, 2020.
Pieri M, Agracheva N, Di Prima AL, et al.: Primary anticoagulation with bivalirudin for patients with implantable ventricular assist devices. Artif Organs 38: 342–346, 2014.
Pappalardo F, Agracheva N, Covello RD, et al.: Anticoagulation for critically ill cardiac surgery patients: is primary bivalirudin the next step? J Cardiothorac Vasc Anesth 28: 1013–1017, 2014.
Baldetti L, Nardelli P, Ajello S, et al.: Anti-thrombotic therapy with cangrelor and bivalirudin in venoarterial extracorporeal membrane oxygenation patients undergoing percutaneous coronary intervention: a single-center experience. ASAIO J 69: e346–e350, 2023.
Vandenbriele C, Arachchillage DJ, Frederiks P, et al.: Anticoagulation for percutaneous ventricular assist device-supported cardiogenic shock: JACC Review Topic of the Week. J Am Coll Cardiol 79: 1949–1962, 2022.
Angleitner P, Simon P, Kaider A, et al.: Impact of bleeding revision on outcomes after left ventricular assist device implantation. Ann Thorac Surg 108: 517–523, 2019.
Mehran R, Rao SV, Bhatt DL, et al.: Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation 123: 2736–2747, 2011.
Kormos RL, Antonides CFJ, Goldstein DJ, et al.: Updated definitions of adverse events for trials and registries of mechanical circulatory support: a consensus statement of the mechanical circulatory support academic research consortium. J Heart Lung Transplant 39: 735–750, 2020.
Patel SR, Saeed O, Naftel D, et al.: Outcomes of restrictive and hypertrophic cardiomyopathies after LVAD: An INTERMACS analysis. J Card Fail 23: 859–867, 2017.
Monaco F, Licheri M, Barucco G, et al.; Collaborators: Four-factor prothrombin complex concentrate in left ventricular assist device implantation: Inverse propensity score-weighted analysis. ASAIO J 69: e293–e300, 2023.
Potapov E, Loforte A, Pappalardo F, et al.: Impact of a surgical approach for implantation of durable left ventricular assist devices in patients on extracorporeal life support. J Card Surg 36: 1344–1351, 2021.